Zynerba pharmaceuticals stock.
Aug 15, 2023 · Of course Zynerba Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders ...
Zynerba Pharmaceuticals, Inc. Stock price Equities ZYNE US98986X1090 Biotechnology & Medical Research Summary Charts News Calendar Company Funds and ETFs Chart …View today's Zynerba Pharmaceuticals Inc stock price and latest ZYNE news and analysis. Create real-time notifications to follow any changes in the live stock price. …According to data from Benzinga Pro, more than 11 million shares have already been traded in the session, far surpassing the stock's 100-day average of 194,930 shares. Zynerba is a pharmaceutical ...See Zynerba Pharmaceuticals, Inc. (ZYNE) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We ...Oct 4, 2023 · Devon, PA, October 4, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc. (“Harmony ... Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.
Zynerba Pharmaceuticals Stock Prediction 2025. The Zynerba Pharmaceuticals stock prediction for 2025 is currently $ 0.950071, assuming that Zynerba Pharmaceuticals shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -26.92% increase in the ZYNE stock price. Oct 4, 2023 · DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips. In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) skyrocketed ...ZYNERBA PHARMACEUTICALS, INC. NONQUALIFIED STOCK OPTION GRANT. ... The Company maintains the Amended and Restated Zynerba Pharmaceuticals, Inc. 2014 Omnibus Incentive Compensation Plan (the “Plan”), which provides the general terms and restrictions for certain equity awards to the Company’s …WebZynerba’s Stock Price Could Decline and Zynerba Could Fail to Meet the Continued Listing Requirements of the Nasdaq Stock Market. ... About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan …Zynerba’s Stock Price Could Decline and Zynerba Could Fail to Meet the Continued Listing Requirements of the Nasdaq Stock Market. ... About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan …
On September 13, 2023, President Terri Sebree of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) sold 12,401 shares of the company's stock.This move comes amidst a year where the insider has sold a ...
Sep 29, 2023 · Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We ...
Aug 15, 2023 · Of course Zynerba Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders ... If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 ...How much profit does Zynerba Pharmaceuticals generate each year? Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a recorded net income of -$35.04 million. ZYNE has generated -$0.80 earnings per share over the last four quarters.DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...Sep 18, 2023 · Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 ... Company profile page for Zynerba Pharmaceuticals Inc including stock price, company news, executives, board members, and contact information
Zynerba Pharmaceuticals. ZYNE. More on Forbes. 0 minute ago. ... Pharmaceutical contract research organization Wuxi XDC gained +36% in its stock market debut in Hong Kong overnight.The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 28,236,148 shares of Zynerba’s common stock were validly tendered and not withdrawn in the tender offer, which represent approximately 52.3% of the total number of shares of Zynerba’s outstanding common stock (not including 1,072,940 ...See Zynerba Pharmaceuticals, Inc. (ZYNE) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.– Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 – – Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET – Devon, PA, May 5, 2021 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, […]Registration Statement No. 333-272805, registering 6,900,000 Shares, issuable pursuant to the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan, filed with the Commission on June ...View our latest analysis for Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is bordering on breakeven, according to the 4 American Pharmaceuticals analysts. They anticipate the company to incur ...
Harmony Biosciences (HRMY) traded lower pre-market Monday after announcing an agreement to acquire Zynerba Pharmaceuticals (ZYNE) for up to $200M cash. Read more here.
Jan 4, 2018 · Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 ... Profile Financials Statistics Dividends Price History Analyst Estimates Insiders Day Low 1.2600 Day High 1.3400 Open: 1.2600 Previous Close 1.2700 52-Week High/Low 1.4000 0.2500 Volume 862,700...Jan 11, 2023 · Zynerba Pharmaceuticals, Inc. is estimated to report earnings on 03/07/2023. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor ... Nov 2, 2022 · DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ... Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids. Zynerba Pharmaceuticals has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases ..., New York City time, on Tuesday, September 26, 2023, a total of 17,298,313 shares of Zynerba's common stock were validly tendered and not withdrawn in the tender offer, which represent ...Zynerba Pharmaceuticals Inc (ZYNE) stock is trading at $0.53 as of 1:51 PM on Thursday, Feb 16, a decline of -$0.01, or -1.46% from the previous closing price of $0.54. The stock has traded between $0.52 and $0.56 so far today. Volume today is less active than usual.Web13.04% of Zynerba Pharmaceuticals stock is owned by insiders. Learn more on ZYNE's insider holdings. Which Zynerba Pharmaceuticals insiders have been selling company stock? The following insiders have sold ZYNE shares in the last 24 months: Armando Anido ($58,074.60), Brian Rosenberger ($20,842.33), Daniel L Kisner …Web
... others are buying or selling, read news, get earnings results, and compare Zynerba Pharmaceuticals against related stocks people have also bought.
Sep 29, 2023 · Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We ...
Zynerba Pharmaceuticals | 4,540 followers on LinkedIn. Advancing Sciences | Improving Connections | Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people …Here's Why Zynerba Pharmaceuticals Stock Soared 356% in the First Half of the Year. Maxx Chatsko | Jul 12, 2019 The marijuana craze has hit this clinical-stage pharmaceutical company.Here's Why Zynerba Pharmaceuticals Lost 21.8% in July Here's Why Zynerba Pharmaceuticals Stock Soared 356% in the First Half of the Year 5 Best Biotech Stocks of 2019 So FarAs previously disclosed, the Offer is to purchase all of the issued and outstanding shares of the common stock, par value $0.001 per share, of Zynerba Pharmaceuticals, Inc. (“Zynerba”).November 14, 2022 at 7:30 AM · 10 min read. Zynerba Pharmaceuticals, Inc. Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome ...Zynerba Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ZYNE) Notice: This company has been marked as potentially delisted and may not be actively trading. Compare Today's Range $1.26 $1.34 50-Day Range $1.21 $1.39 52-Week Range $0.25 $1.40 Volume 862,700 shs Average Volume 515,333 shs Market Capitalization $70.12 million P/E Ratio N/ASep 27, 2023 · , New York City time, on Tuesday, September 26, 2023, a total of 17,298,313 shares of Zynerba's common stock were validly tendered and not withdrawn in the tender offer, which represent ... 11 thg 10, 2023 ... ... Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq: ZYNE). Zynerba is ... stock were validly tendered and not withdrawn in the tender offer ...Corporate – Reverse Stock Split. Zynerba intends to seek approval of a reverse stock split at its Annual Meeting of Stockholders in June (Annual Meeting), which it would effect any time prior to November 1, 2023. Details of the reverse stock split are included in the Company’s Proxy Statement for the Annual Meeting.SAN DIEGO, March 28, 2021 /PRNewswire/ --. Johnson Fistel, LLP is investigating potential claims on behalf of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) ("Zynerba " or the "Company") against ...WebInvestorPlace - Stock Market News, Stock Advice & Trading Tips. In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) skyrocketed ...
Track Zynerba Pharmaceuticals Inc (ZYNE) Stock Price, Quote, latest community messages, chart, news and other stock related information.Zynerba Pharmaceuticals Inc stock price live 1.300, this page displays NASDAQ ZYNE stock exchange data. View the ZYNE premarket stock price ahead of the market session or assess the after hours quote. Harmony’s tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash, or $60 million in the aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million or approximately $2.5444 in additional cash ...Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Instagram:https://instagram. tradovaeis share market open todayparnassus core equity instlfutures funded account Shares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) of Devon were trading at 33 cents per share in late morning trading Wednesday. The company's shareholders will vote on the reverse stock split at ...As previously disclosed, the Offer is to purchase all of the issued and outstanding shares of the common stock, par value $0.001 per share, of Zynerba Pharmaceuticals, Inc. (“Zynerba”). best platform for day tradersbonds quotes Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 ...Oct 10, 2023 · The Zynerba Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. stock soxs Zynerba Pharmaceuticals (Nasdaq:ZYNE) - Stock Price, News & Analysis - Simply Wall St Stocks / Pharmaceuticals & Biotech Zynerba Pharmaceuticals …Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.WebAs previously disclosed, the Offer is to purchase all of the issued and outstanding shares of the common stock, par value $0.001 per share, of Zynerba Pharmaceuticals, Inc. (“Zynerba”).